Advanced search
Publication Cover
mAbs Volume 13, 2021 - Issue 1
Submit an article Journal homepage
9,203
Views
3
CrossRef citations to date
0
Altmetric
Report

Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors

Adam R. Roota BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Gurkan Guntasa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Madan Katragaddaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
James R. Apgara BioMedicine Design, Pfizer Inc., Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0002-4669-0188View further author information
ORCID Icon,
Jatin Narulaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Chew Shun Changa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Sara Hanscoma BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Matthew McKennaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Jason Wadea BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Caryl Meadea BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Weijun Maa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Yongjing Guoa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Yan Liua BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Weili Duana BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Claire Hendershota BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Amy C. Kinga BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Yan Zhanga BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Eric Sousaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Amy Tama BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Susan Benarda BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Han Yanga BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Kerry Kellehera BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Fang Jina BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Nicole Piche-Nicholasa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0003-0695-7965View further author information
ORCID Icon,
Sinead E. Keatingb BioMedicine Design, Pfizer Inc., Dublin, IE, USAView further author information
,
Fernando Narciandib BioMedicine Design, Pfizer Inc., Dublin, IE, USAView further author information
,
Rosemary Lawrence-Hendersonc BioMedicine Design, Pfizer Inc., Andover, MA, USAView further author information
,
Maya Araia BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Wayne R. Stochaja BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Kristine Svensona BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Lidia Mosyaka BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Khetemcnee Lamc BioMedicine Design, Pfizer Inc., Andover, MA, USAView further author information
,
Christopher Francisc BioMedicine Design, Pfizer Inc., Andover, MA, USAView further author information
,
Kimberly Marquettea BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Liliana Wroblewskaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
H. Lily Zhuc BioMedicine Design, Pfizer Inc., Andover, MA, USAView further author information
,
Alfredo Darmanin Sheehanb BioMedicine Design, Pfizer Inc., Dublin, IE, USAView further author information
,
Edward R. LaValliea BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Aaron M. D’Antonaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Alison Bettsa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Lindsay Kingc BioMedicine Design, Pfizer Inc., Andover, MA, USAView further author information
,
Edward Rosfjordd Oncology Research & Development, Pfizer Inc., Pearl River, NY, USAView further author information
,
Orla Cunninghamb BioMedicine Design, Pfizer Inc., Dublin, IE, USAORCID Iconhttps://orcid.org/0000-0002-3888-9541View further author information
ORCID Icon,
Laura Lina BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Puja Saprad Oncology Research & Development, Pfizer Inc., Pearl River, NY, USAView further author information
,
Lioudmila Tchistiakovaa BioMedicine Design, Pfizer Inc., Cambridge, MA, USAView further author information
,
Divya Mathurd Oncology Research & Development, Pfizer Inc., Pearl River, NY, USAView further author information
&
Laird Blooma BioMedicine Design, Pfizer Inc., Cambridge, MA, USACorrespondence[email protected]
View further author information
 show all
Article: 1850395 | Received 13 Jul 2020, Accepted 10 Nov 2020, Published online: 18 Jan 2021

References

  • Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–18. PMID: 28834699182. doi:10.1016/j.pharmthera.2017.08.005.
  • Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–44. PMID: 19509221. doi:10.1158/0008-5472.CAN-09-0547.
  • Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. PMID: 31175342. doi:10.1038/s41573-019-0028-1.
  • Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs PMID: 28071970. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
  • Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104(6):1885–98. PMID: 25821140. doi:10.1002/jps.24430.
  • Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479. PMID: 23468998. doi:10.1371/journal.pone.0057479.
  • Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs. 2013;5(6):882–95. PMID: 23995618. doi:10.4161/mabs.26201.
  • Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. PMID: 28096333. doi:10.1073/pnas.1616408114.
  • Moore PA, Shah K, Yang Y, Alderson R, Roberts P, Long V, Liu D, Li JC, Burke S, Ciccarone V, et al. Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer. Mol Cancer Ther. 2018;17(8):1761–72. PMID: 29866746. doi:10.1158/1535-7163.MCT-17-1086.
  • Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, Jin M, O’Sullivan C, Cummins E, Lambert M, et al. Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies (Basel). 2016;5(1):6. PMID: 31557987. doi:10.3390/antib5010006.
  • Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet K, Emadi A, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2020 Sep 14. Online ahead of print. PMID: 32929488. doi:10.1182/blood.2020007732.
  • Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75. PMID: 30886395. doi:10.1038/s41575-019-0126-x.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. PMID: 26742998. doi:10.3322/caac.21332.
  • Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36(2):170–79. PMID: 15754294. doi:10.1016/j.humpath.2004.12.002.
  • Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, Gao F, Trepicchio WL, Rugge M. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS One. 2017 Dec 19;12(12):e0189953. PMID: 29261789. doi:10.1371/journal.pone.0189953.
  • Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, Duffin KL, Smith CE. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1992;89(3):947–51. PMID: 1346555. doi:10.1073/pnas.89.3.947.
  • Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA, Fok KF, Smith CE, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1993;90(22):10464–68. PMID: 7902563. doi:10.1073/pnas.90.22.10464.
  • Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63(5):941–48. PMID: 1701694. doi:10.1016/0092-8674(90)90497-3.
  • Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. OncoImmunology. 2016;5(10):e1227897. PMID:27853651. doi:10.1080/2162402X.2016.1227897.
  • Almhanna K, Prithviraj GK, Veiby P, Kalebic T. Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. Pharmacol Ther. 2017;170:8–13. PMID: 27765652. doi:10.1016/j.pharmthera.2016.10.007.
  • Mathur D, Root AR, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, Kearney JC, Lucas J, Guffroy M, Golas J, et al. A novel GUCY2C-CD3 T cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clin Cancer Res. 2020;26(9):2188–202. PMID: 31996389. doi:10.1158/1078-0432.CCR-19-3275.
  • Chang CS, Guntas G, Katragadda M, Mathur D, Root AR, Mosyak L, LaVallie ER; Pfizer, Inc., assignee. Antibodies specific for GUCY2C and uses thereof. United States patent application 2019/417,863. 2019 May 21.
  • Apgar JR, Jin F, Katragadda M, Mathur D, Tchistiakova LG; Pfizer, Inc., assignee. Antibodies specific for CD3 and uses thereof. United States patent application 2019/417,589. 2019 May 21.
  • Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010;59(8):1197–209. PMID: 20309546. doi:10.1007/s00262-010-0844-y.
  • Moore GL, Lee SH, Schubbert S, Miranda Y, Rashid R, Pong E, Phung S, Chan EW, Chen H, Endo N, et al. Tuning T cell affinity improves efficacy and safety of anti-CD38 × anti-CD3 bispecific antibodies in monkeys - a potential therapy for multiple myeloma. Blood. 2015;126231798. doi:10.1182/blood.V126.23.1798.1798.
  • Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9(7):617–21. PMID: 8844834. doi:10.1093/protein/9.7.617.
  • Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26–35. PMID: 9231898. doi:10.1006/jmbi.1997.1116.
  • Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan XY, Tchistiakova L. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol. 2011;187(1):561–69. PMID: 21622864. doi:10.4049/jimmunol.1100467.
  • Lund J, Pound JD, Jones PT, Duncan AR, Bentley T, Goodall M, Levine BA, Jefferis R, Winter G. Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma RII. Mol Immunol. 1992;29(1):53–59. PMID: 1530984. doi:10.1016/0161-5890(92)90156-r.
  • Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med. 1991;173(6):1483–91. PMID: 1827828. doi:10.1084/jem.173.6.1483.
  • Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol. 2012;420(3):204–19. PMID: 22543237. doi:10.1016/j.jmb.2012.04.020.
  • Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. PMID: 29271699. doi:10.1080/19420862.2017.1417718.
  • Yeung YA, Krishnamoorthy V, Dettling D, Sommer C, Poulsen K, Ni I, Pham A, Chen W, Liao-Chan S, Lindquist K, et al. An optimized full-length FLT3/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity. Mol Ther. 2020;28(3):889–900. PMID: 31981494. doi:10.1016/j.ymthe.2019.12.014.
  • Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs. 2013;5(3):445–70. PMID: 23571156. doi:10.4161/mabs.24218.
  • Apgar JR, Mader M, Agostinelli R, Benard S, Bialek P, Johnson M, Gao Y, Krebs M, Owens J, Parris K, et al. Beyond CDR-grafting: structure-guided humanization of framework and CDR regions of an anti-myostatin antibody. MAbs. 2016;8(7):1302–18. PMID: 27625211. doi:10.1080/19420862.2016.1215786.
  • Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART(®). Aaps J. 2019;21(4):66. PMID: 31119428. doi:10.1208/s12248-019-0332-z.
  • Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321(6069):522–25. PMID: 3713831. doi:10.1038/321522a0.
  • Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. MAbs. 2009;1(2):128–41. PMID: 20061822. doi:10.4161/mabs.1.2.7631.
  • Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel. 2010;23(7):549–57. PMID: 20457695. doi:10.1093/protein/gzq028.
  • Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaïa N, Ionescu R, Beck A. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem. 2009 Sep 15;392(2):145–54. PMID: 19497295. doi:10.1016/j.ab.2009.05.043.
  • Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine. 1998;16(19):1880–84. PMID: 9795396. doi:10.1016/s0264-410x(98)00173-x.
  • Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008 Apr 4;4(4):e1000048. PMID: 18389056. doi:10.1371/journal.pcbi.1000048.
  • Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 2010;11:568. PMID: 21092157. doi:10.1186/1471-2105-11-568.
  • Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther PMID: 17309332. 2007;7(3):405–18. doi:10.1517/14712598.7.3.405.
  • Cousens L, Terry F, Ardito M, Martin W, De Groot A. In silico high throughput pre-clinical determination of monoclonal antibody immunogenicity (P3391). J Immunol. 2013;190:135.27.
  • Zhang L, Inniss MC, Han S, Moffat M, Jones H, Zhang B, Cox WL, Rance JR, Young RJ. Recombinase-mediated cassette exchange (RMCE) for monoclonal antibody expression in the commercially relevant CHOK1SV cell line. Biotechnol Prog. 2015;31(6):1645–56. doi:10.1002/btpr.2175.
  • Hui GK, Gardener AD, Begum H, Eldrid C, Thalassinos K, Gor J, Perkins SJ. The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions. J Biol Chem. 2019;294(28):10789–806. PMID: 31088911. doi:10.1074/jbc.RA118.007134.
  • Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018;10(5):751–64. PMID: 29634430. doi:10.1080/19420862.2018.1462429.
  • Jones HM, Zhang Z, Jasper P, Luo H, Avery LB, King LE, Neubert H, Barton HA, Betts AM, Webster R. A physiologically-based pharmacokinetic model for the prediction of monoclonal antibody pharmacokinetics from in vitro data. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):738–47. PMID: 31464379. doi:10.1002/psp4.12461.
  • Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development. MAbs. 2013;5(5):787–94. PMID: 23883920. doi:10.4161/mabs.25269.
  • Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11(2):239–64. PMID: 30543482. doi:10.1080/19420862.2018.1553476.
  • Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–38. PMID: 30516432. doi:10.1080/19420862.2018.1556465.
  • Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs. 2013;5(2):237–54. PMID: 23392215. doi:10.4161/mabs.23363.
  • Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun. 2007;355(3):751–57. PMID: 17321501. doi:10.1016/j.bbrc.2007.02.042.
  • Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol. 2013;31(11):612–20. PMID: 23932102. doi:10.1016/j.tibtech.2013.07.002.
  • McConnell AD, Zhang X, Macomber JL, Chau B, Sheffer JC, Rahmanian S, Hare E, Spasojevic V, Horlick RA, King DJ, et al. A general approach to antibody thermostabilization. MAbs. 2014;6(5):1274–82. PMID: 25517312. doi:10.4161/mabs.29680.
  • Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001;305(5):989–1010. PMID: 11162109. doi:10.1006/jmbi.2000.4265.
  • Ewert S, Huber T, Honegger A, Plückthun A. Biophysical properties of human antibody variable domains. J Mol Biol. 2003;325(3):531–53. PMID: 12498801. doi:10.1016/s0022-2836(02)01237-8.
  • Röthlisberger D, Honegger A, Plückthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol. 2005;347(4):773–89. PMID: 15769469. doi:10.1016/j.jmb.2005.01.053.
  • Jung S, Plückthun A. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng. 1997;10(8):959–66. PMID: 9415446. doi:10.1093/protein/10.8.959.
  • Ewert S, Honegger A, Plückthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods. 2004;34(2):184–99. PMID: 15312672. doi:10.1016/j.ymeth.2004.04.007.
  • Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 1996;14(10):1239–45. PMID: 9631086. doi:10.1038/nbt1096-1239.
  • Jung S, Honegger A, Plückthun A. Selection for improved protein stability by phage display. J Mol Biol. 1999;294(1):163–80. PMID: 10556036. doi:10.1006/jmbi.1999.3196.
  • Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106(29):11937–42. PMID: 19571001. doi:10.1073/pnas.0904191106.
  • Lehmann A, Wixted JH, Shapovalov MV, Roder H, Dunbrack RL Jr, Robinson MK. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. MAbs. 2015;7(6):1058–71. PMID: 26337947. doi:10.1080/19420862.2015.1088618.
  • Benschop RJ, Chow CK, Tian Y, Nelson J, Barmettler B, Atwell S, Clawson D, Chai Q, Jones B, Fitchett J, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019;11(6):1175–90. PMID: 31181988. doi:10.1080/19420862.2019.1624463.
  • Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17(3):197–223. PMID: 29192287. doi:10.1038/nrd.2017.227.
  • Ivleva VB, Schneck NA, Gollapudi D, Arnold F, Cooper JW, Lei QP. Investigation of sequence clipping and structural heterogeneity of an HIV broadly neutralizing antibody by a comprehensive LC-MS analysis. J Am Soc Mass Spectrom PMID: 29736600. 2018;29(7):1512–23. doi:10.1007/s13361-018-1968-0.
  • Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008;329(1–2):112–24. PMID: 17996249. doi:10.1016/j.jim.2007.09.017.
  • Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6(2):483–92. PMID: 24492294. doi:10.4161/mabs.27431.
  • Krishna M, Nadler SG. Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol. 2016;7:21. eCollection 2016 PMID: 26870037. doi:10.3389/fimmu.2016.00021.
  • Li L, Li C, Sarkar S, Zhang J, Witham S, Zhang Z, Wang L, Smith N, Petukh M, Alexov E. DelPhi: a comprehensive suite for DelPhi software and associated resources. BMC Biophys. 2012;5:9. PMID: 22583952. doi:10.1186/2046-1682-5-9.
  • Rocchia W, Sridharan S, Nicholls A, Alexov E, Chiabrera A, Honig B. Rapid grid-based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: applications to the molecular systems and geometric objects. J Comput Chem. 2002;23(1):128–37. PMID: 11913378. doi:10.1002/jcc.1161.
  • Rocchia W, Alexov E, Honig B. Extending the applicability of the nonlinear Poisson-Boltzmann equation: multiple dielectric constants and multivalent ions. J Phys Chem B. 2001;105:6507–14. doi:10.1021/jp010454y.
  • Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002;320(2):369–87. PMID: 12079393. doi:10.1016/S0022-2836(02)00442-4.
  • Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33(suppl_2):W382–W388. PMID: 15980494. doi:10.1093/nar/gki387.
  • Sirin S, Apgar JR, Bennett EM, Keating AE. AB-Bind: antibody binding mutational database for computational affinity predictions. Protein Sci. 2016;25(2):393–409. PMID: 26473627. doi:10.1002/pro.2829.
  • Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, Mahon CM, Cummins E, Wade JM, O’Sullivan CM, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol. 2009;388(3):541–58. PMID: 19285987. doi:10.1016/j.jmb.2009.03.019.
  • Kunkel TA, Bebenek K, McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 1991;204:125–39. PMID: 1943776. doi:10.1016/0076-6879(91)04008-c.
  • Finlay WJ, Bloom L, Cunningham O. Optimized generation of high-affinity, high-specificity single-chain Fv antibodies from multiantigen immunized chickens. Methods Mol Biol. 2011;681:383–401. PMID: 20978977. doi:10.1007/978-1-60761-913-0_21.
  • National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): The National Academies Press; 2011. PMID: 21595115. doi:10.17226/12910.
  • Jendeberg L, Nilsson P, Larsson A, Denker P, Uhlén M, Nilsson B, Nygren PA. Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A. J Immunol Methods. 1997;201(1):25–34. PMID: 9032407. doi:10.1016/s0022-1759(96)00215-3.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.